Fig. 3From: GA101 (obinutuzumab) monocLonal Antibody as Consolidation Therapy In CLL (GALACTIC) trial: study protocol for a phase II/III randomised controlled trialSchedule of enrolment, interventions and assessments for participants who are MRD-negative by blood analysis. CT Computed tomography, MRD Minimal residual disease, WHO World Health Organisation. 1If appropriate clinically. 2Tested CentrallyBack to article page